How do the results of CheckMate 9LA and subsequent FDA approval of nivo+ipi+chemo impact your first line management of patients with non-small cell lung cancer?

As many have pointed out, the control arm is no longer SOC and this just adds to numerous ‘me too‘ regimens in frontline non driver mutation NSCLC- atezolizumab, nivo/ipi alone to name a few. It will not greatly impact current practice. If this leads to a price war and brings down the cost of drugs,...

The CheckMate 9LA study showed that combination of chemotherapy + Nivo/Ipi resulted in a survival benefit compared to chemotherapy alone, much like the other key immunotherapy trials in the NSCLC space, (e.g. KEYNOTE-189, IMpower150, POSEIDON). Cross-trial comparisons are difficult to interpret, but...

While I still consider chemotherapy plus pembrolizumab as the best choice (weighing efficacy and toxicity) for most patients with PD-L1 0% or 1-49% driver mutation negative mNSCLC, I have treated 2-3 patients with 9LA, in general, the initial toxicity is higher during the chemo-ipi-nivo phase, howev...

The CheckMate 9LA regimen with ipilimumab and nivolumab with 2 cycles of chemotherapy is a potential choice for front line therapy in a patient who would like to limit chemotherapy. The 2 year survival analysis presented at ASCO demonstrates continued survival benefit over chemotherapy alone. When t...